perioperative outcomes among surgical procedures in renal cancer, renal cell carcinoma, partial nephrectomy, laparoscopic approach, robotic approach, postoperative complications.
AUA 2025, Metastatic Renal Cell Carcinoma (mRCC), Upfront Cytoreductive Nephrectom, Upfront Cytoreductive Nephrectomy With Deferred Systemic Therapy For Metastatic Renal Cell Carcinoma, CARMENA trial,
AUA 2025 performance of minimal residual disease detection with urine-derived DNA, high-grade bladder cancer, recommended repeat TURBT, UroAmp.
AUA 2025, prostate cancer, 18F-DCFPyL, 18F-FDG PET/CT, Heterogeneity of Advanced Prostate Cancer by 18F-DCFPyL and 18F-FDG PET/CT, dual-tracer (¹⁸F-DCFPyL and ¹⁸F-FDG) PET/CT imaging.
AUA 2025, upper tract urothelial carcinoma (UTUC), Tislelizumab, humanized IgG4 anti-PD-1 monoclonal antibody.
AUA 2025, kidney cancer, renal cell carcinoma (RCC), metastatic renal cell carcinoma (mRCC), Nivolumab, Ipilimumab, Nivolumab plus Ipilimumab Therapy, sunitinib, Primary Resistance to Nivolumab plus…
AUA 2025 KEYNOTE-564 trial, clear cell renal cell carcinoma (ccRCC), adjuvant pembrolizumab, partial nephrectomy,
AUA 2025 PSMA-PET imaging to stage men with prostate cancer, regional lymph node involvement, distant metastases, preoperative PSMA-PET imaging, Michigan Urological Surgery Improvement Collaborative (MUSIC),
AUA 2025, Prostate Cancer, Prostate Cancer Risk Groups by PSMA-PET PROMISE (PPP), Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography (PSMA-PET), PROMISE registry.
AUA 2025, prostate cancer, metastatic castration-sensitive prostate cancer (mCSPC), androgen receptor pathway inhibitors (ARPIs), Homologous Recombination Repair (HRR), Homologous Recombination Repair Alterations, AMPLITUDE trial, TALAPRO-3…
AUA 2025, Metastatic Castration-Resistant Prostate Cancer (mCRPC), 177Lu-PSMA Therapy, 225Ac-J591 PSMA-Targeted Radionuclide Therapy, 225Ac-J591 PSMA-Targeted Radionuclide Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with Prior…
